These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 29530933

  • 1. Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
    Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M, TransHERA investigators.
    Clin Cancer Res; 2018 Jul 01; 24(13):3079-3086. PubMed ID: 29530933
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.
    Breast Cancer; 2015 May 01; 22(3):292-9. PubMed ID: 23749689
    [Abstract] [Full Text] [Related]

  • 3. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
    Chumsri S, Sperinde J, Liu H, Gligorov J, Spano JP, Antoine M, Moreno Aspitia A, Tan W, Winslow J, Petropoulos CJ, Chenna A, Bates M, Weidler JM, Huang W, Dueck A, Perez EA.
    Clin Cancer Res; 2018 Jul 01; 24(13):3053-3058. PubMed ID: 29530935
    [Abstract] [Full Text] [Related]

  • 4. Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.
    Feldt M, Bjarnadottir O, Kimbung S, Jirström K, Bendahl PO, Veerla S, Grabau D, Hedenfalk I, Borgquist S.
    J Transl Med; 2015 Apr 29; 13():133. PubMed ID: 25925673
    [Abstract] [Full Text] [Related]

  • 5. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
    Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C, Herceptin Adjuvant (HERA) Trial Study Team.
    Lancet; 2017 Mar 25; 389(10075):1195-1205. PubMed ID: 28215665
    [Abstract] [Full Text] [Related]

  • 6. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
    de Nonneville A, Gonçalves A, Zemmour C, Classe JM, Cohen M, Lambaudie E, Reyal F, Scherer C, Muracciole X, Colombo PE, Giard S, Rouzier R, Villet R, Chopin N, Darai E, Garbay JR, Gimbergues P, Sabiani L, Coutant C, Sabatier R, Bertucci F, Boher JM, Houvenaeghel G.
    Breast Cancer Res Treat; 2017 Apr 25; 162(2):307-316. PubMed ID: 28155054
    [Abstract] [Full Text] [Related]

  • 7. p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.
    Sperinde J, Huang W, Vehtari A, Chenna A, Kellokumpu-Lehtinen PL, Winslow J, Bono P, Lie YS, Petropoulos CJ, Weidler J, Joensuu H.
    Clin Cancer Res; 2018 Jul 01; 24(13):3046-3052. PubMed ID: 29535130
    [Abstract] [Full Text] [Related]

  • 8. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart MJ, Dowsett M, Michiels S, Leyland-Jones B.
    JAMA Oncol; 2016 Aug 01; 2(8):1040-7. PubMed ID: 27100299
    [Abstract] [Full Text] [Related]

  • 9. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
    Kurozumi S, Inoue K, Takei H, Matsumoto H, Kurosumi M, Horiguchi J, Takeyoshi I, Oyama T.
    BMC Cancer; 2015 Sep 07; 15():622. PubMed ID: 26345461
    [Abstract] [Full Text] [Related]

  • 10. Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
    Jeon SH, Shin KH, Kim JH, Kim K, Kim IA, Lee KH, Kim TY, Im SA.
    Breast Cancer Res Treat; 2018 Dec 07; 172(3):619-626. PubMed ID: 30209731
    [Abstract] [Full Text] [Related]

  • 11. Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.
    He X, Ji J, Tian M, Esteva FJ, Hortobagyi GN, Yeung SJ.
    Clin Cancer Res; 2019 Dec 15; 25(24):7388-7395. PubMed ID: 31515457
    [Abstract] [Full Text] [Related]

  • 12. Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients.
    Furrer D, Jacob S, Michaud A, Provencher L, Lemieux J, Diorio C.
    Clin Breast Cancer; 2018 Aug 15; 18(4):e687-e694. PubMed ID: 29275864
    [Abstract] [Full Text] [Related]

  • 13. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
    Carvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V, Fountzilas G, Rimm DL.
    J Natl Cancer Inst; 2015 Aug 15; 107(8):. PubMed ID: 25991002
    [Abstract] [Full Text] [Related]

  • 14. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
    Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, Baehner FL.
    JAMA Oncol; 2016 Jan 15; 2(1):56-64. PubMed ID: 26469139
    [Abstract] [Full Text] [Related]

  • 15. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
    van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, Sonke GS.
    Breast Cancer Res Treat; 2016 Jul 15; 158(2):361-71. PubMed ID: 27357813
    [Abstract] [Full Text] [Related]

  • 16. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S.
    JAMA Oncol; 2015 Jul 15; 1(4):448-54. PubMed ID: 26181252
    [Abstract] [Full Text] [Related]

  • 17. p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy.
    Porter PL, Barlow WE, Yeh IT, Lin MG, Yuan XP, Donato E, Sledge GW, Shapiro CL, Ingle JN, Haskell CM, Albain KS, Roberts JM, Livingston RB, Hayes DF.
    J Natl Cancer Inst; 2006 Dec 06; 98(23):1723-31. PubMed ID: 17148774
    [Abstract] [Full Text] [Related]

  • 18. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
    Villegas SL, Darb-Esfahani S, von Minckwitz G, Huober J, Weber K, Marmé F, Furlanetto J, Schem C, Pfitzner BM, Lederer B, Engels K, Kümmel S, Müller V, Mehta K, Denkert C, Loibl S.
    Breast Cancer Res Treat; 2018 Feb 06; 168(1):179-187. PubMed ID: 29177689
    [Abstract] [Full Text] [Related]

  • 19. IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.
    Reinholz MM, Chen B, Dueck AC, Tenner K, Ballman K, Riehle D, Jenkins RB, Geiger XJ, McCullough AE, Perez EA.
    Clin Cancer Res; 2017 Aug 01; 23(15):4203-4211. PubMed ID: 28533226
    [Abstract] [Full Text] [Related]

  • 20. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
    Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I, Lindquist DL, Holmes FA, Allison MAK, Brooks BD, Portillo RM, Vukelja SJ, Steinberg MS, Stokoe C, Crockett MW, Wang Y, Asmar L, Robert NJ, O'Shaughnessy J.
    Lancet Oncol; 2013 Oct 01; 14(11):1121-1128. PubMed ID: 24007746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.